<h1>AstraZeneca Pharma India Appoints Senior Leadership for Commercial Excellence, Oncology, and Rare Diseases</h1>
AstraZeneca Pharma India Limited has announced significant appointments and promotions within its senior management personnel, strengthening its leadership team across commercial excellence, oncology, and rare diseases. The company approved the appointment of Mr. Mihir Parikh as Director - Commercial Excellence, BD & Strategy, effective August 1, 2026. Simultaneously, Mr. Amay Ashok Pandey was appointed as Director - Oncology Business Unit, commencing September 1, 2026.
The management changes also included a promotion for Mr. Vinay Sharma. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors approved the promotion of Mr. Vinay Sharma to Director - Rare Diseases Business Unit, effective August 1, 2026, having previously served as Business Unit Head - Rare Disease Business Unit.
The appointments and promotions involve senior pharmaceutical industry leaders, each bringing deep experience into their respective therapeutic areas.
Senior Management Profiles
Details regarding the new roles and the profiles of the appointed directors are as follows:| Individual | New Role / Status | Effective Date | Key Expertise Highlights |
|---|---|---|---|
| Mr. Mihir Parikh | Director - Commercial Excellence, BD & Strategy (Appointment) | August 1, 2026 | Biopharmaceutical commercial leader with over 15 years of experience in oncology marketing and commercial strategy; is the Breast Cancer Franchise Lead at AstraZeneca. |
| Mr. Vinay Sharma | Director - Rare Diseases Business Unit (Promotion) | August 1, 2026 | Seasoned healthcare business leader with expertise in strategic launches and franchise building, since assuming the role of Rare Disease Business Unit Head. |
| Mr. Amay Ashok Pandey | Director - Oncology Business Unit (Appointment) | September 1, 2026 | Experienced oncology commercial leader with nearly a decade at AstraZeneca; has extensive background across oncology portfolios and business growth. |
Mr. Mihir Parikh is an alumnus of the Indian School of Business and Rutgers University, possessing experience in engineering and management. His current responsibilities include leading the commercial strategy and growth for ENHERTU.
Mr. Vinay Sharma's background includes pivotal work in shaping the franchise's brand strategy and successfully launching new assets in India, recognizing his prior contributions through leadership awards.
Mr. Amay Ashok Pandey is a seasoned oncology commercial leader who brings significant experience from multinational organizations including Roche, GlaxoSmithKline, Janssen (Johnson & Johnson), and Zydus. His expertise lies in bridging strategy and execution across cross-functional collaboration.
ASTRAZEN Stock Price Movement
Shares of AstraZeneca Pharma India Limited today slipped by 0.76% to close at ₹8236 after trading in the post-market session. The stock saw 1,502 shares change hands during the day's activity.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.